These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 17556838

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Anti-Vascular Endothelial Growth Factor Injection for Exudative Age-related Macular Degeneration in Patients with Vitreo-Macular Traction.
    Querques G.
    Am J Ophthalmol; 2009 Feb; 147(2):375-6; author reply 376-7. PubMed ID: 19166716
    [No Abstract] [Full Text] [Related]

  • 3. Photodynamic therapy in the anti-VEGF era.
    Fine HF.
    Br J Ophthalmol; 2007 Jun; 91(6):707-8. PubMed ID: 17510474
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Age-related macular degeneration.
    Brucker AJ.
    Retina; 2009 Jun; 29(6 Suppl):S2-4. PubMed ID: 19553791
    [Abstract] [Full Text] [Related]

  • 6. Re: development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration.
    Ziemssen F, Heiduschka P, Schraermeyer U, Tübingen Bevacizumab Study Group.
    Retina; 2007 Oct; 27(8):1154-6; author reply 1156-8. PubMed ID: 18040264
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. VEGF and age-related macular degeneration.
    McKay GJ, Silvestri G, Orr N, Chakravarthy U, Hughes AE.
    Ophthalmology; 2009 Jun; 116(6):1227.e1-3. PubMed ID: 19486801
    [No Abstract] [Full Text] [Related]

  • 9. Technology evaluation: pegaptanib, Eyetech/Pfizer.
    Vinores SA.
    Curr Opin Mol Ther; 2003 Dec; 5(6):673-9. PubMed ID: 14755895
    [Abstract] [Full Text] [Related]

  • 10. Ophthalmic Application of Anti-VEGF Therapy.
    Lai TYY, Cheung CMG, Mieler WF.
    Asia Pac J Ophthalmol (Phila); 2017 Dec; 6(6):479-480. PubMed ID: 29204994
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. How to overcome retinal neuropathy: the fight against angiogenesis-related blindness.
    Jo DH, Kim JH, Kim JH.
    Arch Pharm Res; 2010 Oct; 33(10):1557-65. PubMed ID: 21052933
    [Abstract] [Full Text] [Related]

  • 13. Combination therapy using the small interfering RNA bevasiranib.
    Singerman L.
    Retina; 2009 Jun; 29(6 Suppl):S49-50. PubMed ID: 19553802
    [Abstract] [Full Text] [Related]

  • 14. Pathology beyond neovascularization: new targets in age-related macular degeneration.
    Heier JS.
    Retina; 2009 Jun; 29(6 Suppl):S39-41. PubMed ID: 19553799
    [Abstract] [Full Text] [Related]

  • 15. Rationale for combination therapy in age-related macular degeneration.
    Spaide RF.
    Retina; 2009 Jun; 29(6 Suppl):S5-7. PubMed ID: 19553803
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Experience with vascular endothelial growth factor inhibitors used in ophthalmologic care].
    Khalaim AV, Stoliarenko GE.
    Vestn Oftalmol; 2007 Jun; 123(5):54-6, preceding 56. PubMed ID: 18078062
    [No Abstract] [Full Text] [Related]

  • 18. Combination angiostatic therapies: current status.
    Peyman GA, Fiscella R, Conway M.
    Retina; 2009 Jun; 29(6 Suppl):S18-20. PubMed ID: 19553790
    [Abstract] [Full Text] [Related]

  • 19. [VEGF, anti-vEGF and diseases].
    Corvol P.
    Bull Acad Natl Med; 2008 Feb; 192(2):289-300; discussion 300-2. PubMed ID: 18819684
    [Abstract] [Full Text] [Related]

  • 20. Ocular neovascularization: Implication of endogenous angiogenic inhibitors and potential therapy.
    Zhang SX, Ma JX.
    Prog Retin Eye Res; 2007 Jan; 26(1):1-37. PubMed ID: 17074526
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.